News – Page 911 – Endpoints News

Roche sets new deadline for Spark acquisition as divestiture speculation brews

6 years ago

Merck touts Phase III data for antibacterial Recarbrio; Sanofi to ax 200 jobs in Japan — report

6 years ago

Beyond BRCA: AstraZeneca rounds out ESMO with a case for expanded biomarker in prostate cancer

6 years ago

A PhIII Tecentriq win? Not so much, it turns out, as Roche spells out weak data on bladder cancer

6 years ago

Agios lines up solid PhIII data to back Tibsovo's use in bile duct cancer — ahead of planned sNDA

6 years ago

Vertex continues shopping, spending $20M upfront to access Ribometrix's RNA-drugging platform

6 years ago

Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure

6 years ago

Charging at blockbuster Advair, Novartis boasts topline victories for asthma drugs in twin PhIII studies

6 years ago

Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it

6 years ago

FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?

6 years ago

CRISPR pioneer Feng Zhang's upstart biotech seeks $100M-plus IPO for preclinical base editing work

6 years ago

Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat ...

6 years ago

Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises — but can they actually beat Pfizer's ...

6 years ago

Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO

6 years ago

AstraZeneca heralds Tagrisso's OS lead over old TKIs in lung cancer niche

6 years ago

PRIMA vs PAOLA: GSK and Merck/AstraZeneca square off in a high-profile PARP showdown at ESMO

6 years ago

Seattle Genetics' armed antibody scores high in frontline bladder cancer, taking center stage at ESMO

6 years ago

Another big biopharma merger runs into another snag at the FTC. What now?

6 years ago

Bristol-Myers Squibb boasts impressive 5-year melanoma OS data on Opdivo/Yervoy combo, though it still can't pinpoint ...

6 years ago

Amgen isn’t wowing ESMO with the latest KRAS G12C update — but maybe there are more important issues at stake

6 years ago

Bristol-Myers Squibb's Opdivo couldn't topple Nexavar in HCC — but will better safety profile win over physicians?

6 years ago

NASH hopeful Genfit promotes Dean Hum to president; Immune Therapeutics CEO passes baton to successor

6 years ago

OND reorganization moves forward

6 years ago

Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent?

6 years ago

First page Previous page 908 909 910911912 913 914 Next page Last page